Arvind leads the Drug Discovery and Development efforts at Xaira. Prior to Xaira, he led Large Molecule Drug Discovery at Genentech where he was responsible for protein and antibody discovery and engineering, and some oligonucleotide and cell therapeutics.  Before Genentech he has led similar functions across large organizations like Bristol-Myers Squibb and Pfizer.  

‍

Arvind has a long standing interest in antibody based therapeutics and has been involved in the discovery and development of several approved molecules.  He has led teams that have been involved in establishing several technologies, i.e. site-specific conjugation for antibody drug conjugates, charge based hetero-dimerization for antibody bispecifics, and conditionally activated antibodies using pH switches.  His current interests include de novo antibody design and computational multi-parameter optimization to enable the next generation of antibody discovery and engineering.  In graduate school, he trained in protein biophysics and biochemistry and conducted postdoctoral studies in immunology studying negative selection at University of California at Berkeley.  His undergraduate degree is in Chemistry and Computer Science.

‍